bf/NASDAQ:KMDA_icon.jpeg

COM:KAMADA

Kamada Pharmaceuticals

  • Stock

USD

Last Close

5.85

22/11 21:00

Market Cap

339.10M

Beta: -

Volume Today

30.97K

Avg: -

Company Overview

Metric
Company NameKamada Ltd.Dexcel Pharma
SymbolKMDA
MSH IDCOM:KAMADACOM:DEXCEL
MarketSTOCKSPRIVATE
SectorHealthcareHealthcare & Health Services
IndustryDrug Manufacturers - Specialty & GenericPharmaceuticals
CountryILIL
Stage
Employee Count378
Websitekamada.comdexcel.com
LinkedInkamadadexcel-pharma
Founders

Market Metrics

Metric
Market Cap339.10M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Financial Performance

Metric
Revenue144.76M
Revenue (LTM)
Revenue (NTM)
Gross Profit52.59M
EBITDA24.07M
Operating Income11.16M
Net Income8.28M
EPS0.17
Diluted EPS0.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin0.42
Operating Profit Margin0.11
EBITDA Margin0.17
Net Profit Margin0.10
Return on Equity0.06
Return on Assets0.04
Return on Capital Employed0.05

Valuation Multiples

Metric
P/E Ratio42.09
P/B Ratio1.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio2.38
EV Multiple19.16

Operational Metrics

Metric
Days Sales Outstanding64.45
Days Payables Outstanding49.14
Days Inventory Outstanding363.17
Operating Cycle416.90
Cash Conversion Cycle332.82
Asset Turnover0.44

Cash Flow Metrics

Metric
Operating Cash Flow4.38M
Free Cash Flow-1.56M
Cash Flow to Debt13.48
Operating Cash Flow/Sales0.13
Free Cash Flow Yield0.01

Balance Sheet Metrics

Metric
Cash & Equivalents55.18M
Accounts Receivable6.79M
Inventory87.75M
Goodwill30.06M
Debt to Capitalization0.04
Debt to Assets0.02
Current Ratio4.11
Quick Ratio2.14

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue0.01
R&D to Revenue0.09
SG&A to Revenue0.09